Skip to main content
Richard Silver, MD, Oncology, New York, NY, New York-Presbyterian Hospital

RichardT.SilverMD

Oncology New York, NY

Hematologic Oncology

Professor, Medicine, Weill Cornell Medical College

Dr. Silver is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Silver's full profile

Already have an account?

  • Office

    NewYork-Presbyterian/Weill Cornell Medical Center
    533 East 70th Street Starr Pavilion, 3rd Floor
    New York, NY 10034
    Phone+1 646-962-2700
  • Is this information wrong?

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1956 - 1958
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 1953 - 1954
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1953

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1954 - 2025
  • PA State Medical License
    PA State Medical License 1983 - 1984
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolit...
    Richard T. Silver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Recombinant Interferon-_ Reduces Thrombotic Events in Patients with Polycythemia Vera
    Richard T. Silver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermedi...
    Richard T. Silver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Press Mentions

  • Dave Boule Confronted Polycythemia Vera with an Accountant’s Consistency
    Dave Boule Confronted Polycythemia Vera with an Accountant’s ConsistencyJune 17th, 2022
  • Cancer Pill Could Keep Patients Alive for More Than 10 Years, New Study Finds
    Cancer Pill Could Keep Patients Alive for More Than 10 Years, New Study FindsMarch 10th, 2017
  • 'Imatinib Changed Everything'
    'Imatinib Changed Everything'March 8th, 2017
  • Join now to see all

Hospital Affiliations